"I love Functional Fluidics | Tools to Predict, Select, and Monitor"

2022-05-25 02:12:29

About Us Services Biomarkers Flow Adhesion Mechanical Fragility Flow Thrombosis Flow Adhesion Dynamic Flow Adhesion Reverse Flow Adhesion Characterization Flow Adhesion Avidity Contract Research Contract Research Pre-Clinical Validation Clinical Studies Post Marketing Studies RBC Test Menu Clinical Provider Clinical Send Out Testing Clinical Send Out Process Scientific Resources Peer Review Publications Abstracts ELIPSIS News Newsletter Careers Contact Us Functional Fluidics Defining Red Blood Cell Health About UsIn Healthcare today, there is a tremendous need for well-validated biomarkers to objectively monitor red blood cell health. At Functional Fluidics our red blood cell function biomarker support these evolving needs.Functional Fluidics is a high complexity CLIA-certified diagnostic lab. Our mission is to be the gold standard in red blood cell health starting with Sickle Cell Disease.Our suite of assays is currently offered nationally to clinical providers, pharmaceutical, academic and biotech partners to support drug development and patient care.Learn MoreBiomarkerSFunctional Fluidics’ proprietary biomarkers are unique diagnostic platforms that assess red blood cell health by replicating the environment that red blood cells experience in our bodies. Our biomarker provide indices that determine health of the patient.Adhesion Test: Measures the stickiness of RBCs within a whole blood sample under physiologic flow conditions and generates an adhesion index. Mechanical Fragility Tests: Measures the ability of RBCs to survive physiologic stress and generates a mechanical fragility index (MFI).Learn MoreContract Research ServicesFunctional Fluidics provides Contract Research Services to pharmaceutical, BioTech and Academic Research companies. We are well-positioned to address the needs of clients with large-scale validation studies and to provide insights into the individual patient-level response critical for development of personalized medical applications.Our suite of proprietary cell function assays can help validate assumptions or support clinical claims. If your organization is in the Pre-Clinical, Clinical or Post-Marketing research stage, you can benefit from our biomarkers and our expertise in defining Red Blood Cell Health.Learn MoreSEND OUT TESTINGFunctional Fluidics offers Send Out Testing services to Clinical Providers. The test data is then used for patient monitoring as a clinical support tool.Healthcare providers partner with Functional Fluidics to gain access to well-validated biomarkers to objectively assess the impact on red blood cell health, and ultimately their patients’ health.Learn MoreSOLUTIONS FOR OUR PARTNERSClinical ProvidersDiagnosis and ongoing patient monitoring as a clinical toolLEARN MOREPharmaContract Research Services leveraging our proprietary biomarker assays to support the advancement of red blood cell therapies.LEARN MORE Insurance PayersImproving patient lives while reducing the inefficiencies and costs across the healthcare network.LEARN MOREInvestor RelationsAs we continue our growth, we invite those interested in investing our expansion to engage with our teamLEARN MORENews & Media May 4, 2022 Functional Fluidics CEO & Founder, Patrick Hines, to be featured in the Michigan Celebrates Angels event April 22, 2022 Sickle Cell Speaks: Mechanism of Sickle Cell Disease April 1, 2022 Red blood cell biomarkers may predict sickle cell disease (SCD) severity and the risk of vaso-occlusive crisis, according to a study that evaluated the FA-WB-VCAM blood test. OverviewThis short video describes the origins of the company, based on research in the Hines Lab at Wayne State University. We have developed a suite of assays that address the need for better ways to assess blood function, starting with the experience of Dr. Hines as a Pediatric ICU Physician at Detroit Medical Center. Business & Scientific PartnershipsWhy Choose Functional Fluidics? Proprietary Lab Tests CLIA Certified Lab Complex Tests Experience Thought Leader Access Specialized Staff Strong Industry RelationshipsFunctional Fluidics AssaysOur suite of proprietary cell function assays can help validate assumptions or support clinical claims.Flow Adhesion of whole blood on VCAM-1 (FA-WB-VCAM)LEARN MOREFlow Adhesion of whole blood on P-Selectin (FA-WB-Psel)LEARN MOREMechanical Fragility – Normoxia (MF)LEARN MOREEvaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS)Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.LEARN MOREEvaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and BiomarkersFunctional Fluidics Biomarker Featured in ELIPSIS article in American Society of Hematology (ASH) Blood MagazineKey PointsFeasibility of monitored out-of-hospital pain and patient-reported VOC days as endpoints for clinical trials in SCD is demonstrated.ePROs, actigraphy, and laboratory biomarkers enable improved identification and assessment of in-hospital and out-of-hospital VOCs.LEARN MOREPublicationsFLOW ADHESIONEvaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and BiomarkersThis non interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.Read MoreMECHANICAL FRAGILITYRed Blood Cell Mechanical Fragility as Potential Metric for Assessing Blood Damage Caused by Implantable Durable Ventricular Assist Devices: Comparison of Two Types of Centrifugal Flow Left Ventricular Assist Devices.Implantable Ventricular Assist Devices (VADs) have become a treatment of choice for patients with end-stage heart failure or cardiogenic shock, significantly increasing both survival rates and the quality of life of patients.Read MoreMECHANICAL FRAGILITYIndividual Variability in Response to a Single Sickling Event for Normal, Sickle Cell, and Sickle Trait ErythrocytesHemoglobin S (Hb-S) polymerization is the primary event in sickle cell disease causing irreversible damage to red blood cell (RBC) membranes over repeated polymerization cycles.Read MoreFLOW ADHESIONSevuparin blocks sickle blood cell adhesion and sickleleucocyte rolling on immobilized L-selectin in a dose dependent mannerAdhesion of sickle red blood cells (SSRBC) to the vascular endothelium may initiate and propagate vascular obstruction in sickle cell disease (SCD)Read MoreMECHANICAL FRAGILITYImpact of Environment on Red Blood Cell ability to Withstand Mechanical Stress.Susceptibility of red blood cells (RBC) to hemolysis under mechanical stress is represented by RBC mechanical fragility (MF), with different types or intensities of stress potentially emphasizing different perturbations of RBC membranesRead MoreMECHANICAL FRAGILITYAn Approach to Measuring RBC Haemolysis and Profiling RBC Mechanical FragilityRed blood cells (RBC) can be damaged by medical products, from storage or from disease. Haemolysis (cell rupture and haemoglobin release) is often a key indicator, with mechanical fragility (MF) offering the potential to assess sub-haemolytic damage as wellRead MoreFLOW ADHESIONLow Molecular Weight Heparin Inhibits Sickle Erythrocyte Adhesion to VCAM-1 through VLA-4 Blockade in a Standardized Microfluidic Flow Adhesion AssayThe vaso-occlusive events in sickle cell disease (SCD) begin in early childhood, warranting the need for more preventative and therapeutic interventions for those affectedRead MoreMECHANICAL FRAGILITYImpact of the Oscillating Bead Size and Shape on Induced Mechanical Stress on Red Blood Cells and Associated Hemolysis in Bead MillingWhile in circulation, red blood cells (RBC) need to elastically undergo large deformations without lysing, an ability that may be compromised by cell membrane damage.Read MorePLEASE COMPLETE THE FORM BELOW FOR MORE INFORMATION: May 16, 2018 Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dosedependent manner November 17, 2016 Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose Dependent Manner September 16, 2016 Impact of environment on Red Blood Cell ability to withstand mechanical stress Contact UsOur Location440 Burroughs Street,Suite 641Detroit, MI48202United StatesEmail: [email protected]:313-315-2555Subscribe to Our Newsletter Biomarkers Services Publications Contact Us © Copyright Functional Fluidics 2016.